Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Five Key Questions for Board Meetings

As public companies conduct spring board meetings, no topic looms larger than the effects of the coronavirus pandemic and how it is transforming the global economy. The way your organization’s leadership navigates this period of change is likely to determine its overall health once things settle into the “new normal.” At Weaver, we are committed…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Five Key Questions for Board Meetings

As public companies conduct spring board meetings, no topic looms larger than the effects of the coronavirus pandemic and how it is transforming the global economy.

The way your organization’s leadership navigates this period of change is likely to determine its overall health once things settle into the “new normal.”

At Weaver, we are committed to ensuring that you are empowered to lead your organization to the best of your ability. We provide the information and insights you need to thoroughly prepare for your next board meeting, ask the right questions and determine appropriate plans of action based on the most critical unfolding topics and trends.

The following five questions can help guide your next board meeting so that you can respond to rapidly changing events in a productive and thorough way.

1. Do we have a plan for financial disclosures related to the effects of COVID-19?

The SEC has encouraged registrants to disclose the effect of the COVID-19 pandemic on their financial results. Regulatory relief is available for companies impacted by the coronavirus, but companies must file certain forms to qualify. SEC guidance for public companies also addresses disclosures surrounding changes to annual shareholder meetings and more.

2. Are we prepared for current and future supply chain disruptions?

Your supply chain is likely to have been affected by COVID-19. Whether or not you were prepared, now is the time to thoroughly assess possible lingering impacts, prepare for the likely economic downturn to come and agree on a plan to adjust to future disruptions. Find potential alternatives and develop creative and cost-effective ways to map your supply network. Take the pandemic into account when evaluating supplier performance and be proactive when planning for the future.

3. Are our IT systems secure?

Are you doing enough to protect your operations from cyber threats? Bad actors aren’t sympathetic to the stressors placed on your organization or business by the spread of COVID-19. In fact, they’re stepping up their efforts to try and take advantage of the chaos.

As remote work requirements rise and your incident response processes are strained, other factors like pandemic-specific phishing campaigns and more will further test your employees and your overall preparedness. Here are eight CIO considerations to take into account as you review your preparedness.

4. Are we considering ESG reporting in our reporting and planning?

Environmental, social and governance (ESG) reporting shows investors that your company is taking these issues into account and playing an active role in bringing these initiatives into their core strategies. If you do not disclose and communicate these efforts, your company will not be positioned to take advantage of potential future benefits for growth, access to capital and more.

Are you aware of market-driven ESG reporting frameworks that can ensure you’re communicating effectively? Is your board equipped to assist your company in better addressing ESG issues and taking advantage of accelerating ESG investing?

5. Is our business continuity plan up to date?

Determine how you’ll respond to COVID-19 at every level, accounting for staff absences and leave, employee education, the capabilities of your remote-oriented operations, public relations factors and more. Be sure to communicate this information through as many channels as possible to your workforce, shareholders and customers.

Weaver offers information and insights to prepare for your next board meeting. We can help you ask the right questions and determine appropriate plans of action based on topics and trends as they unfold. Subscribe to our monthly insights for articles and information to help you review your organization’s operations and prepare for change in an uncertain world.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512